BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 38292487)

  • 1. Tumor cell metabolic reprogramming and hypoxic immunosuppression: driving carcinogenesis to metastatic colonization.
    Katopodi T; Petanidis S; Anestakis D; Charalampidis C; Chatziprodromidou I; Floros G; Eskitzis P; Zarogoulidis P; Koulouris C; Sevva C; Papadopoulos K; Dagher M; Karakousis VA; Varsamis N; Theodorou V; Mystakidou CM; Vlassopoulos K; Kosmidis S; Katsios NI; Farmakis K; Kosmidis C
    Front Immunol; 2023; 14():1325360. PubMed ID: 38292487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cancer metabolic reprogramming and immune response.
    Xia L; Oyang L; Lin J; Tan S; Han Y; Wu N; Yi P; Tang L; Pan Q; Rao S; Liang J; Tang Y; Su M; Luo X; Yang Y; Shi Y; Wang H; Zhou Y; Liao Q
    Mol Cancer; 2021 Feb; 20(1):28. PubMed ID: 33546704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Tumor Metabolic Reprogramming in Tumor Immunity.
    Zhang X; Song W; Gao Y; Zhang Y; Zhao Y; Hao S; Ni T
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manipulating T-cell metabolism to enhance immunotherapy in solid tumor.
    Chen C; Wang Z; Ding Y; Qin Y
    Front Immunol; 2022; 13():1090429. PubMed ID: 36618408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment.
    Zhu Y; Li X; Wang L; Hong X; Yang J
    Front Endocrinol (Lausanne); 2022; 13():988295. PubMed ID: 36046791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lactate-Lactylation Hands between Metabolic Reprogramming and Immunosuppression.
    Chen L; Huang L; Gu Y; Cang W; Sun P; Xiang Y
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic reprogramming in the tumor microenvironment of liver cancer.
    Lin J; Rao D; Zhang M; Gao Q
    J Hematol Oncol; 2024 Jan; 17(1):6. PubMed ID: 38297372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance.
    Wei F; Wang D; Wei J; Tang N; Tang L; Xiong F; Guo C; Zhou M; Li X; Li G; Xiong W; Zhang S; Zeng Z
    Cell Mol Life Sci; 2021 Jan; 78(1):173-193. PubMed ID: 32654036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lactate-related metabolic reprogramming and immune regulation in colorectal cancer.
    Sun Q; Wu J; Zhu G; Li T; Zhu X; Ni B; Xu B; Ma X; Li J
    Front Endocrinol (Lausanne); 2022; 13():1089918. PubMed ID: 36778600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic reprogramming in the immunosuppression of tumor-associated macrophages.
    Wang Y; Wang D; Yang L; Zhang Y
    Chin Med J (Engl); 2022 Oct; 135(20):2405-2416. PubMed ID: 36385099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functions and mechanisms of lactylation in carcinogenesis and immunosuppression.
    Su J; Zheng Z; Bian C; Chang S; Bao J; Yu H; Xin Y; Jiang X
    Front Immunol; 2023; 14():1253064. PubMed ID: 37646027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
    Bahrambeigi S; Shafiei-Irannejad V
    Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving Cancer Immunotherapy: Exploring and Targeting Metabolism in Hypoxia Microenvironment.
    Wei J; Hu M; Du H
    Front Immunol; 2022; 13():845923. PubMed ID: 35281061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment.
    Sasidharan Nair V; Saleh R; Toor SM; Cyprian FS; Elkord E
    Cancer Immunol Immunother; 2021 Aug; 70(8):2103-2121. PubMed ID: 33532902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy.
    Yan L; Tan Y; Chen G; Fan J; Zhang J
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy.
    Huang L; Xu H; Peng G
    Cell Mol Immunol; 2018 May; 15(5):428-437. PubMed ID: 29553135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy.
    Zhou Y; Yuan J; Xu K; Li S; Liu Y
    ACS Nano; 2024 Jan; 18(3):1846-1864. PubMed ID: 38180952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment.
    Ma G; Zhang Z; Li P; Zhang Z; Zeng M; Liang Z; Li D; Wang L; Chen Y; Liang Y; Niu H
    Cell Commun Signal; 2022 Jul; 20(1):114. PubMed ID: 35897036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in metabolic reprogramming of NK cells in the tumor microenvironment on the impact of NK therapy.
    Miao L; Lu C; Zhang B; Li H; Zhao X; Chen H; Liu Y; Cui X
    J Transl Med; 2024 Mar; 22(1):229. PubMed ID: 38433193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into the Effect of Catalytic Intratumoral Lactate Depletion on Metabolic Reprogramming and Immune Activation for Antitumoral Activity.
    Zhao J; Tian Z; Zhao S; Feng D; Guo Z; Wen L; Zhu Y; Xu F; Zhu J; Ma S; Hu J; Jiang T; Qu Y; Chen D; Liu L
    Adv Sci (Weinh); 2023 Feb; 10(4):e2204808. PubMed ID: 36479819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.